Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris [Phase 3]

View source ↗

Summary

Phase 3 trial update for topical FMX101 in moderate-to-severe acne vulgaris has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• FMX101 (FMX101)

Snippet

Sponsor: Vyne Therapeutics Inc. | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2020-02-21